Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Feb 15, 2021; 13(2): 119-130
Published online Feb 15, 2021. doi: 10.4251/wjgo.v13.i2.119
Published online Feb 15, 2021. doi: 10.4251/wjgo.v13.i2.119
Characteristic | Standard therapy, n = 70, (%) | TNT, n = 82, (%) | P value | |
pCR | 5 (7) | 19 (23) | 0.007 | |
CR | 7 (10) | 23 (26) | 0.009 | |
NAR score | mean [SD] | 16.8 [12.9] | 10.7 [10.8] | 0.002 |
NAR classes | < 8 | 9 (13) | 35 (43) | < 0.001 |
8-16 | 38 (56) | 33 (40) | ||
> 16 | 21 (31) | 14 (17) | ||
Surgery | R0 | 65 (93) | 78 (95) | 0.4451 |
R1 | 4 (6) | 4 (5) | ||
R2 | 1 (1) | 0 (0) | ||
Weeks to stoma closure | mean [SD] | 32.8 [18.6] | 20.1 [10.9] | < 0.001 |
- Citation: Tuta M, Boc N, Brecelj E, Peternel M, Velenik V. Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure. World J Gastrointest Oncol 2021; 13(2): 119-130
- URL: https://www.wjgnet.com/1948-5204/full/v13/i2/119.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i2.119